

Stanford



Nathaniel Myall

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICES

- **Medicine**

300 Pasteur Dr Rm JC007

Stanford, CA 94305

Tel (650) 725-5071 Fax (650) 725-5849

- **Stanford Cancer Center**

875 Blake Wilbur Dr

Clinic A MC 6560

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 498-5800

Bio

CLINICAL FOCUS

- Oncology
- Lung Cancer
- Neuroendocrine Tumors

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

HONORS AND AWARDS

- Humanism in Hematology/Oncology Award, Division of Oncology, Stanford Hospital and Clinics (2019)
- Methods in Clinical Cancer Research Workshop, ASCO/AACR (2019)
- Charles Dorsey Armstrong Award for Excellence in Patient Care by a Senior Resident, Department of Internal Medicine, Stanford Hospital and Clinics (2015)

PROFESSIONAL EDUCATION

- Board Certification, Hematology, American Board of Internal Medicine (2019)
- Board Certification, Oncology, American Board of Internal Medicine (2019)
- Board Certification, Internal Medicine, American Board of Internal Medicine (2015)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2019) CA
- Residency, Stanford University, Internal Medicine Residency, CA (2015)
- Medical Education: Stanford University School of Medicine (2012) CA

Research & Scholarship

CLINICAL TRIALS

- Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer, Not Recruiting

Publications

PUBLICATIONS

- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022; OP2200128
- **Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.** *Journal of neuro-oncology*
Hui, C., Qu, V., Wang, J. Y., von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lu, J. T., Li, G., Hayden-Gephart, M., Wakelee, H., Neal, J., Ramchandran, et al
2022
- **Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.** *JCO precision oncology*
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., Henry, S., Wood, D., Stehr, H., Ji, H., Nagpal, S., Hayden Gephart, M., Wakelee, et al
2022; 6: e2200220
- **Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.** *Federal practitioner : for the health care professionals of the VA, DoD, and PHS*
Myall, N. J., Wang, S. X., Hall, E. T., Witteles, W. H., Leung, L., Dunn, T. J., Hong, W. J.
2022; 39 (Suppl 3): S56-S62
- **Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment.** *JCO precision oncology*
Giustini, N. P., Patel, S. P., Myall, N. J., Fernando do Prado Moura, J., Kulkarni, A., Chao, R. C., Wakelee, H., Bazhenova, L.
2022; 6: e2100551
- **Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.** *JCO precision oncology*
Dankner, M., Wang, Y., Fazelzad, R., Johnson, B., Nebhan, C. A., Dagogo-Jack, I., Myall, N. J., Richtig, G., Bracht, J. W., Gerlinger, M., Shinozaki, E., Yoshino, T., Kotani, et al
2022; 6: e2200107
- **Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.** *Clinical lung cancer*
Waliy, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., Li, C., Pagtama, J., Tisch, A. H., Neal, J. W.
2022
- **Implementation and efficacy of a fellow-led, case-based noon lecture series.**
Dickerson, J., Myall, N., Roy, M., Johnson, T.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.** *International journal of radiation oncology, biology, physics*
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., Neal, J., Wakelee, H., Chin, A., Diehn, M., Loo, B. W., Chang, D. T., Pollom, et al
2022
- **Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.** *Translational lung cancer research*
Gu, X., Wang, W., Wu, W., Zhang, Y., Shao, L., Santarpia, M., Christopoulos, P., Myall, N. J., Shi, Z., Lou, G.
2022; 11 (5): 902-909
- **In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*

- Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al
1800; 17 (2): e12-e14
- **Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies.** *Neuro-oncology advances*
Myall, N. J., Yu, H., Soltys, S. G., Wakelee, H. A., Pollom, E.
2021; 3 (Suppl 5): v52-v62
 - **Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al
2021
 - **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Waliyany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.
2021
 - **Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series.** *Translational lung cancer research*
Myall, N. J., Lei, A. Q., Wakelee, H. A.
2021; 10 (1): 487-95
 - **Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.** *Clinics in chest medicine*
Myall, N. J., Das, M.
2020; 41 (2): 211-22
 - **Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer** *LUNG CANCER*
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N. J., Sasane, M., Dalal, A., Culver, K., Wozniak, A. J., Baik, C. S., Mutebi, A., Zhang, P., Wakelee, et al
2019; 128: 74-90
 - **Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.** *Clinical lung cancer*
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., Wakelee, H. A.
2018
 - **-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.** *oncologist*
Baik, C. S., Myall, N. J., Wakelee, H. A.
2017
 - **Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer** *TRANSLATIONAL CANCER RESEARCH*
Myall, N. J., Wakelee, H. A.
2016; 5: S1233-S1240
 - **Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.** *Clinical lung cancer*
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., Diehn, M., Wakelee, H. A.
2016; 17 (2): e17-21
 - **Variations in the neurobiology of reading in children and adolescents born full term and preterm** *NEUROIMAGE-CLINICAL*
Travis, K. E., Ben-Shachar, M., Myall, N. J., Feldman, H. M.
2016; 11: 555-565
 - **Developmental Changes within White Matter Tracts of Healthy Children Age 9 to 16 Years Old**
Yeatman, J. D., Myall, N. J., Dougherty, R. F., Wandell, B. A., Feldman, H. M.
LIPPINCOTT WILLIAMS & WILKINS.2013: S5
 - **Case series: fractional anisotropy along the trajectory of selected white matter tracts in adolescents born preterm with ventricular dilation.** *Journal of child neurology*
Myall, N. J., Yeom, K. W., Yeatman, J. D., Gaman-Bean, S., Feldman, H. M.

2013; 28 (6): 771-777

- **Tract Profiles of White Matter Properties: Automating Fiber-Tract Quantification** *PLOS ONE*

Yeatman, J. D., Dougherty, R. F., Myall, N. J., Wandell, B. A., Feldman, H. M.

2012; 7 (11)

- **G328E and G409E sialin missense mutations similarly impair transport activity, but differentially affect trafficking** *MOLECULAR GENETICS AND METABOLISM*

Myall, N. J., Wreden, C. C., Wlizla, M., Reimer, R. J.

2007; 92 (4): 371-374